Healthcare Industry News: Halozyme Therapeutics
News Release - May 16, 2007
Halozyme Therapeutics Names Randal J. Kirk and Kathryn E. Falberg to Board of DirectorsSAN DIEGO, May 16 (HSMN NewsFeed) -- Halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that Randal J. Kirk and Kathryn E. Falberg have been named to its Board of Directors. Mr. Kirk was Founder, Chairman of the Board, President, and CEO of New River Pharmaceuticals, Inc. (Nasdaq: NRPH ), which recently sold to Shire plc for $2.6 billion. Ms. Falberg is the former CFO of Amgen.
"We are thrilled to welcome RJ and Kate to our Board of Directors," said Jonathan Lim, MD, Halozyme's President and CEO. "Their addition to our Board is timely, as Halozyme enters into this exciting period of growth and transformation into an innovation-driven company with a pipeline of its own products. RJ brings over 20 years of successful management, financial, and entrepreneurial experience to Halozyme. He has been an incredibly supportive shareholder and we welcome his wisdom and experience to our Board. Kate is a very experienced and talented finance executive, having served as CFO at Amgen, Applied Magnetics, and Inamed. Her many years of strategic and financial experience helping manage growth at Amgen will serve us very well."
Mr. Kirk has over 20 years of experience in the health care industry. Previously, Mr. Kirk co-founded General Injectables & Vaccines, Inc. (GIV), a pharmaceutical distributor, in 1983 and served as Chairman of the board of GIV prior to the sale of that company in 1998. Mr. Kirk served as a member of the board of directors of Scios, Inc. (previously traded on Nasdaq and acquired by Johnson & Johnson for $2.4 billion) between February 2000 and May 2002. Mr. Kirk also currently serves as Senior Managing Director of Third Security, LLC, an investment management firm founded by Mr. Kirk. In addition, he has served as a member of the board of directors of Clinical Data, Inc. since September 2002, and as chairman of its board since December 2004. He has served on the board of directors of the Radford University Foundation, Inc. since September 1998, the Virginia Bioinformatics Institute Policy Advisory Board since March 2004, and the Board of Visitors of Radford University since July 2003. He serves on a number of other foundations, as well. Mr. Kirk received his B.A. in Business from Radford University and his J.D. from the University of Virginia.
Ms. Falberg has over 23 years of financial experience. Ms. Falberg joined Amgen, a global biotechnology company, in 1995 as Treasurer, and advanced through a series of positions of increasing responsibility, culminating in her appointment as Senior Vice President, Finance, and Chief Financial Officer in 1998. At Amgen, over a period of almost seven years, Ms. Falberg played a key role in shaping strategy as the company grew from $1.6 billion to $4.0 billion in revenues, and from $7 billion to $70 billion in market capitalization. Prior to Amgen, Ms. Falberg served as Vice President, Chief Financial Officer and Treasurer of Applied Magnetics Corporation. After her retirement from Amgen, she was a consultant to Inamed, a medical device company (previously traded on the Nasdaq and acquired by Allergan for $3.2 billion), and briefly served as its interim Chief Financial Officer. She has served on the board of directors of VISX, Human Genome Sciences, and Fresh Del Monte Produce. Ms. Falberg received her M.B.A. and her B.A. in Economics from the University of California, Los Angeles.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the drug delivery, palliative care, oncology, and infertility markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition, the company has received FDA approval for two products: Cumulase® and Hylenex, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning our strategy and vision) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.
Source: Halozyme Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.